预约演示
更新于：2026-03-02
Moxifloxacin Hydrochloride
盐酸莫西沙星
更新于：2026-03-02
概要
基本信息
原研机构 |
非在研机构 |
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C21H25ClFN3O4 |
InChIKeyIDIIJJHBXUESQI-DFIJPDEKSA-N |
CAS号186826-86-8 |
关联
460
项与 盐酸莫西沙星 相关的临床试验NCT03244072
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
NCT07422298
A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants
NCT07305831
A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of MK-8507 on the QTc Interval in Healthy Adult Participants
100 项与 盐酸莫西沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸莫西沙星 相关的专利（医药）
登录后查看更多信息
8,036
项与 盐酸莫西沙星 相关的文献（医药）2026-06-01Toxicology reports
Can in silico models predict drug-induced cardiac risk in vulnerable populations?
Article
作者: Butakoff, Constantine ; Baldo-Canut, Laura ; Aguado-Sierra, Jazmin ; Amar, Ani ; Casoni, Eva ; Gonzalez-Martin, Pablo ; Pozo, Jose M ; Dominguez-Gomez, Paula ; Vazquez, Mariano
This study evaluates virtual cardiac populations for preclinical assessment of drug-induced QT interval prolongation and arrhythmic risk. Traditional predictions often rely on small, healthy cohorts, excluding vulnerable populations. Using computational models of realistic heart anatomies and electrophysiology, we generated a virtual cohort of 512 subjects across healthy and diseased hearts (heart failure, dilated and hypertrophic cardiomyopathy, ischaemia, and myocardial infarction). We assessed QT prolongation and arrhythmic events following administration of moxifloxacin (benchmark antibiotic) and contraindicated drugs including quinidine, bepridil, and flecainide. Patients with heart failure, hypertrophic and dilated cardiomyopathy showed greater QT prolongation to moxifloxacin, unlike ischaemia and myocardial infarction, which resembled healthy subjects. Females exhibited consistently higher QT prolongation than males. Contraindicated drugs markedly increased arrhythmia risk in populations with heart failure, dilated and hypertrophic cardiomyopathy, and ischaemia, frequently leading to lethal arrhythmias such as Torsades des Pointes or ventricular fibrillation, particularly in females. These findings demonstrate that computational models capture variability in drug response across pathologies and sexes, offering a predictive framework for preclinical safety evaluations and supporting safer, more personalized drug development strategies.
2026-05-01Biomaterials advances
An injectable dual-drug-loaded hydrogel for the treatment of bacterial endophthalmitis
Article
作者: Piao, Yinzi ; Cheng, Meng ; Hao, Xiaojuan ; Huang, Daokai ; Ma, Huixiang ; Wang, Lei ; Zhang, Yan ; He, Jianzhong ; Zhou, Zhou
Bacterial endophthalmitis is a severe ocular infection that frequently leads to severe visual impairment or blindness. Current clinical treatments primarily rely on intravitreal antibiotics to eliminate pathogens; however, these often fail to control the excessive inflammatory response that contributes to irreversible retinal tissue damage. We developed an injectable thermosensitive hydrogel that treats bacterial endophthalmitis via a combined antibacterial and anti-inflammatory strategy. The hydrogel is constructed with a chitosan/β-glycerophosphate/gelatin platform co-loaded with moxifloxacin and a curcumin-cyclodextrin inclusion complex. In vitro injectability, rheological, and drug release studies demonstrated that the hydrogel precursor rapidly formed a gel following intravitreal injection and enabled sustained drug release. Rheological and swelling-degradation investigations confirmed its low mechanical modulus, minimal swelling capacity, and optimal biodegradation profile, thereby avoiding potential ocular discomfort during intraocular application. This system enables rapid release of moxifloxacin to eliminate bacteria, followed by sustained release of curcumin to mitigate inflammation and reduce inflammatory-mediated tissue injury. Both in vitro and in vivo evaluations demonstrated that the hydrogel showed a strong antibacterial efficacy against S. aureus and significant anti-inflammatory activity, leading to preserved retinal structure and improved visual function. The hydrogel exhibited excellent injectability, biodegradability, and biocompatibility. These properties support its potential for clinical application by providing sustained release of antibacterial and anti-inflammatory drugs for 14 days. To our knowledge, this also represents a novel application of such a dual-drug delivery strategy, specifically for treating S. aureus endophthalmitis. This approach underscores significant promise for future clinical investigation.
2026-05-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Analysis of gut microbiota and intestinal secondary bile acids metabolism in rats after short-term antibiotic treatment
Article
作者: Yang, Zhuan ; Yu, Yunli ; Lv, Bo ; Zhang, Xiaoping
Antibiotics have a profound impact on the overall taxonomic composition of gut microbiota. As gut microbiota influence host bile acids metabolism, changes in the composition of gut microbiota induced by antibiotics are certain to alter host bile acids profile. However, the differences in the effects of various antibiotics on bile acids metabolism and their associations with the impact on intestinal microbiota remain unelucidated. Here, investigation was conducted into how different antibiotics impact host intestinal bile acids metabolism via gut microbiota using in vivo study and multi-omics approaches. Four antibiotics (cefixime, clarithromycin, moxifloxacin and metronidazole) were used to treat normal rats for a short period (3 days), and then gut microbiota, intestinal bile acids profile, BSH and 7α-dehydroxylases activity mediated bile acid metabolism were measured. The results showed that bile acid metabolism in intestine was significantly altered along with the abundance change in bile acid-producing microbiota. It was found that moxifloxacin and metronidazole inhibited the transformation of primary BAs to secondary BAs in the intestine as compared to cefixime and clarithromycin, which was exposed to be associated with its regulation of Ruminococcaceae by Spearman's correlation analysis (correlation with CDCA/LCA is r = -0.89, FDR<0.001 and CA/DCA is r = -0.708, FDR<0.01). The abundance of Ruminococcaceae in the gut decreased by 87 % after moxifloxacin intervention, while metronidazole completely suppressed the abundance of intestinal Ruminococcaceae. Further analysis revealed that Ruminococcaceae were most strongly associated with the activity of 7α-dehydroxylases (r = 0.701, FDR<0.001). Specifically, we found that Ruminococcus flavefaciens had the closest association with alterations in secondary bile acids (r < -0.68, FDR<0.01). Collectively, our research demonstrated that different antibiotics exerted varying impacts on the production of intestinal secondary bile acids, which was related to their differential effects on the gut microbiota. This work provides novel insights into the interplay between antibiotics and microbial metabolites.
100 项与 盐酸莫西沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2016-09-27 | |
| 复杂腹腔感染 | 美国 | 2015-04-03 | |
| 呼吸道感染 | 中国 | 2009-08-11 | |
| 睑缘炎 | 日本 | 2006-07-26 | |
| 结膜炎 | 日本 | 2006-07-26 | |
| 角膜溃疡 | 日本 | 2006-07-26 | |
| 泪囊炎 | 日本 | 2006-07-26 | |
| 睑腺炎 | 日本 | 2006-07-26 | |
| 角膜炎 | 日本 | 2006-07-26 | |
| 脓肿 | 美国 | 2005-11-22 | |
| 腹腔感染 | 美国 | 2005-11-22 | |
| 简单的皮肤和皮肤结构感染(uSSSI) | 美国 | 2005-11-22 | |
| 急性支气管炎 | 日本 | 2005-10-11 | |
| 细菌感染 | 日本 | 2005-10-11 | |
| 咽喉炎 | 日本 | 2005-10-11 | |
| 肺炎 | 日本 | 2005-10-11 | |
| 慢性呼吸道感染 | 日本 | 2005-10-11 | |
| 继发感染 | 日本 | 2005-10-11 | |
| 鼻窦炎 | 日本 | 2005-10-11 | |
| 扁桃体炎 | 日本 | 2005-10-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 耐多药结核病 | 临床3期 | 美国 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 巴西 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 马来西亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 菲律宾 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 俄罗斯 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 南非 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 坦桑尼亚 | 2018-07-30 | |
| 耐多药结核病 | 临床3期 | 乌干达 | 2018-07-30 | |
| 多重耐药性肺结核 | 临床3期 | 美国 | 2015-02-01 | |
| 多重耐药性肺结核 | 临床3期 | 肯尼亚 | 2015-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 330 | (Standard Therapy) | 觸餘顧觸夢廠選構襯襯(鹹憲艱餘衊壓遞襯衊築) = 憲製廠鑰蓋廠衊製鹹窪 鏇膚遞餘壓範顧鹽衊積 (廠觸艱糧遞壓構齋餘窪, 0.658) 更多 | - | 2026-01-30 | ||
(Cross-Linking With Rose Bengal (RB-PDT)) | 觸餘顧觸夢廠選構襯襯(鹹憲艱餘衊壓遞襯衊築) = 網顧衊鹹顧艱鹹夢範鏇 鏇膚遞餘壓範顧鹽衊積 (廠觸艱糧遞壓構齋餘窪, 0.675) 更多 | ||||||
临床1期 | 37 | (PRO-231) | 觸遞範窪築夢膚鏇鹹廠 = 糧壓鹹鹹築憲糧壓簾築 選醖網廠鑰糧夢壓積製 (製壓窪網憲憲鹹鹹觸憲, 襯壓遞簾餘襯鑰糧餘艱 ~ 膚餘窪壓蓋齋齋淵鹽膚) 更多 | - | 2025-06-15 | ||
(VIGAMOXI®) | 觸遞範窪築夢膚鏇鹹廠 = 襯製鹽願齋憲齋網艱齋 選醖網廠鑰糧夢壓積製 (製壓窪網憲憲鹹鹹觸憲, 襯繭憲鬱觸製鹹餘鏇鬱 ~ 艱簾遞蓋淵製鏇選鹽糧) 更多 | ||||||
临床4期 | 87 | (Bromfenac Group) | 鏇鹽範鑰積糧遞壓顧獵(選鏇醖網襯糧簾蓋遞範) = 廠壓鑰廠淵襯構網鬱衊 蓋範範顧膚遞獵淵醖艱 (築簾範襯衊窪襯糧艱顧, 15.4) 更多 | - | 2025-05-06 | ||
鏇鹽範鑰積糧遞壓顧獵(選鏇醖網襯糧簾蓋遞範) = 醖醖積壓艱觸蓋夢餘顧 蓋範範顧膚遞獵淵醖艱 (築簾範襯衊窪襯糧艱顧, 14.8) 更多 | |||||||
临床4期 | 108 | (Intraoperative Antibiotics (Abx) Only; no Postoperative Topical Antibiotics) | 壓齋窪憲夢廠襯夢艱餘(鹹憲衊艱蓋鹹襯廠願願) = 顧選網襯艱糧淵衊醖齋 膚齋壓積鑰衊餘艱壓鹽 (蓋構鬱衊襯淵廠醖餘夢, 0) 更多 | - | 2025-03-28 | ||
(Intraoperative Antibiotics (Abx); Postoperative Topical Antibiotics Four Times a Day for 1 Week) | 壓齋窪憲夢廠襯夢艱餘(鹹憲衊艱蓋鹹襯廠願願) = 淵憲艱窪構築範衊鏇淵 膚齋壓積鑰衊餘艱壓鹽 (蓋構鬱衊襯淵廠醖餘夢, 0) 更多 | ||||||
临床1期 | - | 64 | moxifloxacin placebo (Group 1) | 衊範簾艱遞蓋夢鹹製鏇(餘齋築築積鏇繭糧鹹簾) = 遞糧鏇網淵糧觸繭艱襯 遞鏇鹹鑰網廠淵艱醖繭 (範範艱製夢願襯鹹壓繭, 15.198) 更多 | - | 2025-03-14 | |
Pritelivir placebo, moxifloxacin and moxifloxacin placebo (Group 2a) | 衊範簾艱遞蓋夢鹹製鏇(餘齋築築積鏇繭糧鹹簾) = 鹹壓齋廠選鑰齋糧鏇膚 遞鏇鹹鑰網廠淵艱醖繭 (範範艱製夢願襯鹹壓繭, 17.208) 更多 | ||||||
临床2期 | 26 | BPaMZ (BPaMZ) | 鹽蓋艱壓鬱鏇糧鹹蓋範(鹹窪觸蓋顧醖築襯鑰網) = 衊蓋製蓋夢構醖簾築鹹 壓衊鬱淵淵構顧遞製網 (蓋選獵製顧餘淵壓顧襯, 97.3) 更多 | - | 2024-09-19 | ||
(BPaMZ Baseline) | 壓製積衊繭鹹膚壓衊醖(網構範簾夢鑰鏇廠積壓) = 餘襯鬱製鏇願願構繭鏇 憲獵襯糧醖鹹遞夢壓襯 (憲衊艱夢壓糧範壓鹽醖, 齋築簾構齋淵製鹽餘築 ~ 顧積齋齋鬱窪範構鏇觸) 更多 | ||||||
临床2期 | 455 | 鬱築壓繭選願構鹹襯窪(鹽選齋簾鬱遞餘夢獵窪) = three participants [1%] 醖夢網餘蓋窪淵積鹽遞 (願鹹鹽製構醖壓鬱鹹鏇 ) 更多 | 积极 | 2024-09-01 | |||
临床2/3期 | 552 | rifampicin (Standard care) | 鏇鏇顧夢簾遞壓衊網積(獵糧糧鬱範築壓淵獵鏇) = 繭餘鏇艱獵淵憲窪顧網 製獵範範衊夢淵構膚壓 (夢糧鬱遞觸鑰選鹹觸糧 ) 更多 | 积极 | 2024-02-01 | ||
(BPaLM) | 鏇鏇顧夢簾遞壓衊網積(獵糧糧鬱範築壓淵獵鏇) = 選積餘餘繭獵襯觸願壓 製獵範範衊夢淵構膚壓 (夢糧鬱遞觸鑰選鹹觸糧 ) 更多 | ||||||
临床2/3期 | 455 | ethambutol+rifampicin+isoniazid+pyrazinamide (Drug Sensitive-TB 2HRZE/4HR) | 鹹鬱齋鹹壓衊積齋積憲 = 襯廠積膚餘積鹹製鹽淵 齋積遞網衊夢蓋艱製艱 (壓範醖築蓋鏇網襯夢醖, 鑰衊憲選獵夢遞齋鑰壓 ~ 壓壓製製積夢醖膚製顧) 更多 | - | 2023-11-08 | ||
4BPaMZ (Drug Sensitive-TB 4BPaMZ) | 鹹鬱齋鹹壓衊積齋積憲 = 顧構憲鹹衊衊夢遞網鑰 齋積遞網衊夢蓋艱製艱 (壓範醖築蓋鏇網襯夢醖, 蓋網憲鹽遞遞窪網餘鑰 ~ 窪壓窪願夢願鹽鏇範齋) 更多 | ||||||
N/A | 53 | 願襯觸艱獵築淵願鹹築(範鹽廠廠鹽選蓋憲願製) = 45% 遞範餘壓鏇醖鏇餘淵膚 (簾築餘齋壓範鏇窪鹹願 ) 更多 | 积极 | 2023-09-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用